| Literature DB >> 35453228 |
Joana Ferreira1, Ana Isabel Placido2, Vera Afreixo3, Inês Ribeiro-Vaz4,5,6, Fátima Roque2,7, Maria Teresa Herdeiro8.
Abstract
Adverse drug reactions (ADR) significantly impact mortality and morbidity and lead to high healthcare costs. Reporting ADR to regulatory authorities allows for monitoring the safety and efficacy profile of medicines on the market and for assessing the benefit-risk ratio. This retrospective study aims to characterize the ADR profile of the most consumed antibiotics in Portugal that are prescribed for upper airway infections and submitted to the EudraVigilance database. The variables were analyzed in an exploratory perspective, through absolute and relative frequencies, with emphasis on serious ADR. A total of 59,022 reports were analyzed of which 64.4% were classified as suspected serious ADR. According to serious ADR, the female sex (52.2%) and 18-64 age group (47.5%) prevail. Health professionals reported 87.8% of suspected serious ADR and European Economic Area (EEA) countries represented 50.8% of the reports. "Skin and subcutaneous tissue connections" (15.9%), "general disorders and administrations site conditions" (12%), and "gastrointestinal disorders" (9.8%) are the prevalent system organ classes. In 4.5% of the reports, patients had a fatal outcome. A periodic evaluation of the safety of the antibiotic should be performed to facilitate the development of guidelines and policies to reduce the frequency of serious ADR.Entities:
Keywords: EudraVigilance database; adverse drug reactions; antibiotics; upper airway infections
Year: 2022 PMID: 35453228 PMCID: PMC9028170 DOI: 10.3390/antibiotics11040477
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Annual characterization of EudraVigilance reports of amoxicillin, amoxicillin + clavulanic acid, azithromycin, cefazolin, clarithromycin, and levofloxacin.
| Amoxicillin | Amoxicillin + Clavulanic Acid | Azithromycin | Cefazolin | Ciprofloxacin | Clarithromycin | Levofloxacin | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total (%) | Serious | Total | Serious | Total | Serious | Total | Serious | Total | Serious | Total | Serious | Total | Serious | Total | Serious | ||
| Year | 2017 | 3180 | 2329 | 4406 | 3069 | 1120 | 853 | 580 | 458 | 2777 | 2153 | 1601 | 1188 | 3239 | 2674 |
| |
| 2018 | 4041 | 1981 | 5242 | 3069 | 1247 | 641 | 466 | 335 | 2963 | 1709 | 1666 | 855 | 2740 | 1891 |
| ||
| 2019 | 5115 | 2772 | 5867 | 3418 | 1711 | 1011 | 544 | 414 | 3606 | 2181 | 1958 | 1033 | 4953 | 3948 |
| ||
| Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| Sex | Male | 4603 | 2639 | 6228 | 3891 | 1492 | 994 | 704 | 525 | 4083 | 2640 | 1743 | 1087 | 5036 | 3919 |
| |
| Female | 7218 | 4013 | 8322 | 4856 | 2396 | 1355 | 848 | 649 | 4933 | 3147 | 3230 | 1790 | 5257 | 4014 |
| ||
| Not specified | 515 | 430 | 965 | 809 | 190 | 156 | 38 | 33 | 330 | 256 | 252 | 199 | 639 | 580 |
| ||
| Age Group | 0–1 month | 22 | 18 | 26 | 18 | 19 | 16 | 5 | 4 | 5 | 3 | 4 | 2 | 3 | 3 |
| |
| 2 months–2 years | 848 | 324 | 661 | 289 | 215 | 149 | 15 | 9 | 38 | 23 | 116 | 47 | 19 | 16 |
| ||
| 3–11 years | 952 | 413 | 921 | 463 | 379 | 245 | 33 | 19 | 106 | 82 | 279 | 153 | 46 | 43 |
| ||
| 12–17 years | 390 | 216 | 421 | 246 | 139 | 80 | 48 | 35 | 116 | 84 | 120 | 74 | 136 | 108 |
| ||
| 18–64 years | 5627 | 3307 | 7481 | 4584 | 1879 | 1074 | 826 | 626 | 4760 | 3059 | 2507 | 1413 | 5055 | 3966 |
| ||
| 65–85 years | 2372 | 1429 | 3303 | 2119 | 687 | 437 | 499 | 385 | 2645 | 1763 | 1212 | 789 | 3592 | 2713 |
| ||
| More than 85 | 499 | 326 | 967 | 642 | 108 | 83 | 68 | 45 | 518 | 370 | 200 | 139 | 798 | 606 |
| ||
| Not specified | 1626 | 1049 | 1735 | 1195 | 652 | 421 | 96 | 84 | 1158 | 659 | 787 | 459 | 1283 | 1058 |
| ||
| Reporter group | Health professional | 10,152 | 6444 | 13,422 | 8765 | 2929 | 2026 | 1563 | 1188 | 6648 | 4577 | 3857 | 2581 | 9609 | 606 |
| |
| Other | 2184 | 20 | 2093 | 19 | 1149 | 11 | 27 | 0 | 2698 | 25 | 1368 | 13 | 1323 | 1058 |
| ||
| Geographic origin | EEA | 9552 | 4368 | 11495 | 5571 | 2390 | 852 | 1055 | 678 | 6773 | 3509 | 3830 | 1726 | 4935 | 2581 |
| |
| Non-EEA | 2784 | 2714 | 4020 | 3985 | 1688 | 1653 | 535 | 529 | 2573 | 2534 | 1395 | 1350 | 5997 | 5932 |
| ||
EEA—European Economic Area.
Figure 1Suspected serious ADR distributed by the different system organ class for each active substance.
Distribution of the SOC skin and subcutaneous tissue disorders, general disorders and administration site conditions, and gastrointestinal disorders by age and sex.
| Age Group | Sex | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| MedDRA SOCs | 0–1 Month | 2 Months–2 Years | 3–11 Years | 12–17 Years | 18–64 Years | 65–85 Years | More than 85 Years | Male | Female |
| Gastrointestinal disorders | 7 | 242 | 452 | 280 | 5989 | 2614 | 420 | 4057 | 6668 |
| General disorders and administration site conditions | 16 | 233 | 527 | 294 | 7454 | 3314 | 495 | 5674 | 7392 |
| Skin and subcutaneous tissue disorders | 13 | 611 | 1059 | 516 | 9290 | 4034 | 902 | 7089 | 9966 |
MeDRA SOCs- Medical Dictionary for Regulatory Activities System Organ and Classes.
Most frequent Preferred Term according to the most prevalent system organ and class or Amoxicillin, Amoxicillin + clavulanic acid, azithromycin, cefazolin, ciprofloxacin, clarithromycin, and levofloxacin.
| General Disorders and Administration Site Conditions | General Disorders and Administration Site Conditions | Skin and Subcutaneous Tissue Disorders | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred Term | Diarrhea | Nausea | Vomiting | Pyrexia | Drug Ineffective | Drug Interaction | Pruritus | Rash | Urticaria | Erythema | |
| Active Substances | |||||||||||
| Amoxicillin | 267 | 206 | 222 | 234 | 105 | 81 | 498 | 1060 | 538 | 256 | |
| Amoxicillin + clavulanic acid | 619 | 309 | 466 | 353 | 295 | 80 | 626 | 1289 | 762 | 430 | |
| azithromycin | 179 | 126 | 129 | 112 | 206 | 90 | 120 | 168 | 86 | 47 | |
| cefazolin | 10 | 13 | 14 | 34 | 30 | 13 | 41 | 81 | 49 | 61 | |
| ciprofloxacin | 305 | 319 | 173 | 215 | 299 | 242 | 218 | 344 | 143 | 149 | |
| clarithromycin | 207 | 200 | 165 | 126 | 140 | 298 | 99 | 164 | 95 | 80 | |
| levofloxacin | 203 | 265 | 261 | 293 | 220 | 154 | 390 | 551 | 202 | 178 | |
Distribution of suspected ADR reports related to seriousness by age, sex, and active substance.
| Death (%) | Life-Threatening (%) | Hospitalization (Initial or Prolonged) (%) | Persistent or Significant Disability or Incapacity | Congenital Anomaly (%) | Medically Important Event or Reaction (%) | ||
|---|---|---|---|---|---|---|---|
| Amoxicillin | 126 (1.8) | 490 (6.9) | 2495 (35.2) | 64 (0.9) | 13 (0.2) | 3894 (55.0) | |
| Amoxicillin + Clavulanic acid | 358 (3.7) | 711 (7.4) | 3464 (36.2) | 101 (1.1) | 8 (0.1) | 4914 (51.4) | |
| Azithromycin | 128 (5.1) | 134 (5.3) | 869 (34.7) | 56 (2.2) | 7 (0.3) | 1311 (52.3) | |
| Cefazoline | 62 (5.1) | 332 (27.5) | 419 (34.7) | 3 (0.2) | 1 (0.1) | 390 (32.3) | |
| Ciprofloxacin | 287 (4.7) | 360 (6.0) | 2152 (35.6) | 487 (8.1) | 5 (0.1) | 2752 (45.5) | |
| Clarithromycin | 127 (4.1) | 168 (5.5) | 1091 (35.5) | 83 (2.7) | 3 (0.1) | 1604 (52.1) | |
| Levofloxacin | 632 (7.4) | 621 (7.3) | 3249 (38.2) | 491 (5.8) | 3 (0.0) | 3517 (41.3) | |
| Age groups | 0–1 month | 6 (9) | 8 (12) | 21 (33) | 2 (3) | 1 (2) | 26 (4) |
| 2 months–2 years | 23 (3) | 30 (4) | 305 (36) | 8 (12) | 9 (1) | 487 (57) | |
| 3–11 years | 33 (2) | 77 (5) | 499 (35) | 15 (1) | 6 (0) | 788 (56) | |
| 12–17 years | 17 (2) | 72 (9) | 330 (39) | 14 (2) | 0 (0) | 410 (49) | |
| 18–64 years | 776 (4) | 1556 (9) | 6259 (35) | 701 (4) | 6 (0) | 8731 (48) | |
| 65–85 years | 548 (6) | 806 (8) | 4349 (45) | 375 (4) | 0 (0) | 3557 (37) | |
| More than 85 | 161 (7) | 137 (6) | 119 (54) | 58(3) | 3(0) | 660 (30) | |
| SEX | Female | 698 (3.5) | 1483 (7.5) | 1277 (8.1) | 691 (3.5) | 14 (0.1) | 9806 (49.5) |
| Male | 938 (6) | 556 (3.5) | 6242 (39.8) | 556 (3.5) | 16 (0.1) | 6666 (42.5) | |